News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abbott Laboratories (ABT) Accused of Racketeering in Epilepsy Drug Marketing Suit



8/19/2013 8:06:14 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Abbott Laboratories (ABT:US) allegedly engaged in racketeering when it led an effort to market the epilepsy drug Depakote for unapproved uses, according to a federal court complaint filed in Chicago. The pharmaceutical company last year agreed to pay $1.6 billion to settle state and federal claims it promoted the drug’s use to treat bi-polar mania and to prevent migraine headaches. “Unfortunately, these sanctions were insufficient to compensate” for harm caused to injured claimants, according to today’s complaint by three health-benefit plans seeking to represent those claimants as a group.

Help employers find you! Check out all the jobs and post your resume.

Read at BusinessWeek


comments powered by Disqus
Abbott
 
 
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES